Staphylococcal Scalded Skin Syndrome in Emergency Medicine Medication

  • Author: Randall W King, MD, FACEP; Chief Editor: Rick Kulkarni, MD   more...
 
Updated: May 4, 2010
 

Medication Summary

Drug therapy for staphylococcal scalded skin syndrome (SSSS) consists of parenteral antibiotics to cover S aureus, which is considered the primary source of the toxin-mediated syndrome.

Topical therapy with agents, such as fusidic acid and/or mupirocin, can be used as adjuncts to parenteral antibiotics, but they should not be used alone in true cases of staphylococcal scalded skin syndrome (SSSS).

Next

Antibiotics

Class Summary

When the susceptibility of the organism is not yet known, the DOC is a penicillinase-resistant synthetic penicillin (eg, nafcillin). However, should the organism show susceptibility to penicillin G, then that drug should be chosen as the main course of therapy. A first-generation cephalosporin can be used as an alternative. In penicillin-allergic patients, macrolides or aminoglycosides may be substituted. Increasing rates of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) associated infections warrants consideration for vancomycin therapy in patients who initially appear toxic or who fail to respond to nafcillin.

Sulfamethoxazole and trimethoprim (Bactrim, Bactrim DS, Cotrim, Cotrim DS, Septra, Septra DS)

 

Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid.

View full drug information

Nafcillin (Nafcil, Unipen)

 

Treats infections caused by penicillinase-producing staphylococci, and thus is DOC for penicillin G-resistant staphylococcal infections. Do not use for treatment of penicillin G-susceptible staphylococci. Use parenteral therapy initially in severe infections, using very high doses for very severe infections.

View full drug information

Penicillin G procaine (Crysticillin, Wycillin)

 

Long-acting parenteral penicillin (IM only) indicated in treatment of moderately severe infections caused by penicillin G-sensitive microorganisms. Useful in treatment of moderately severe infections of skin and skin structures. In adults, administer by deep IM injection only into upper, outer quadrant of buttock. In infants and small children, midlateral aspect of thigh may be better site for administration.

Amoxicillin and clavulanate (Clavulin, Augmentin)

 

Drug combination that extends antibiotic spectrum of this penicillin to include bacteria normally resistant to beta-lactam antibiotics. Indicated for skin and skin-structure infections caused by beta-lactamase-producing strains of S aureus. In children >3 mo, base dose on amoxicillin content. Because of different amoxicillin-to-clavulanic acid ratios in 250-mg tablets (250/125) vs 250-mg chewable tablets (250/62.5), do not use 250-mg tablet until child weighs >40 kg.

View full drug information

Cefazolin (Ancef, Kefzol, and Zolicef)

 

First-generation semisynthetic cephalosporin, which, by binding to one or more penicillin-binding proteins, arrests bacterial cell wall synthesis and inhibits bacterial growth. Primarily active against skin flora, including S aureus. Typically used alone for skin and skin-structure coverage. Total daily dosages are same for IV/IM routes.

View full drug information

Cephalexin (Keflex, Biocef)

 

First-generation cephalosporin that inhibits bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls. Primarily active against skin flora. Typically used for skin-structure coverage and as prophylaxis in minor procedures.

View full drug information

Clindamycin (Cleocin)

 

Lincosamide useful as treatment against serious skin and soft-tissue infections caused by most staphylococci strains. Inhibits bacterial protein synthesis by inhibiting peptide chain initiation at bacterial ribosome, where it binds preferentially to 50S ribosomal subunit, inhibiting bacterial growth.

View full drug information

Gentamicin (Garamycin, Gentacidin)

 

Aminoglycoside antibiotic used for gram-negative bacterial coverage. Commonly used in combination with both agent against gram-positive organisms and one that covers anaerobes.

Not antibiotic of first choice. Consider using only if penicillins or other less toxic drugs are contraindicated, when bacterial susceptibility tests and clinical judgment indicate its use, and in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms.

Dosing regimens are numerous and are adjusted based on CrCl and changes in volume of distribution, as well as body space into which agent needs to distribute. Dose of gentamicin may be given IV/IM. Each regimen must be followed by at least trough level drawn on third or fourth dose, 0.5 h before dosing; may draw peak level 0.5 h after 30-min infusion.

View full drug information

Tobramycin (Nebcin)

 

Used in skin, bone, and skin-structure infections caused by S aureus, Pseudomonas aeruginosa, Proteus species, Escherichia coli, Klebsiella species, and Enterobacter species. Indicated in serious staphylococcal infections when penicillin or other potentially less toxic drugs contraindicated and when bacterial susceptibility testing and clinical judgment indicate use. To prevent increased toxicity caused by excessive blood levels do not exceed 5 mg/kg/d, unless serum levels monitored.

View full drug information

Erythromycin (E-mycin, Ery-Tab, Erythrocin)

 

Indicated for treatment of infections caused by susceptible strains including S aureus. Inhibits RNA-dependent protein synthesis, possibly by stimulating dissociation of peptidyl t-RNA from ribosomes. This inhibits bacterial growth.

Age, weight, and severity of infection determine proper dosage. When bid dosing desired, half of total daily dose may be taken q12h. For more severe infections, double dose.

View full drug information

Vancomycin (Vancocin)

 

Indicated for patients who cannot receive or have failed to respond to penicillins and cephalosporins or have infections with resistant staphylococci. To avoid toxicity, current recommendation is to assay vancomycin trough levels after third dose drawn 0.5 h prior to next dosing. Use creatinine clearance to adjust dose in patients diagnosed with renal impairment.

Used in conjunction with gentamicin for prophylaxis in penicillin-allergic patients undergoing gastrointestinal or genitourinary procedures.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Randall W King, MD, FACEP  Assistant Clinical Professor of Emergency Medicine, The University of Toledo College of Medicine; Director, Emergency Medicine Residency Program, Associate Chair, Department of Emergency Medicine, St Vincent Mercy Medical Center

Randall W King, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Council of Emergency Medicine Residency Directors, Ohio State Medical Association, and Society for Academic Emergency Medicine

Disclosure: Challenger corporation None Physician Advisory Board; Ohio ACEP Consulting fee Editor Rivers review text Emergency Medicine

Coauthor(s)

Paul R de Saint Victor, MD, FACEP  Chief of Staff, St Vincent Mercy Medical Center, Toledo

Paul R de Saint Victor, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Heart Association, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Daniel J Dire, MD, FACEP, FAAP, FAAEM  Clinical Professor, Department of Emergency Medicine, University of Texas-Houston; Clinical Professor, Department of Pediatrics, University of Texas Health Sciences Center, San Antonio, Texas

Daniel J Dire, MD, FACEP, FAAP, FAAEM is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American Academy of Pediatrics, American College of Emergency Physicians, and Association of Military Surgeons of the US

Disclosure: Talecris Biotherapeutics Honoraria Speaking and teaching

Francisco Talavera, PharmD, PhD  Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Jeter (Jay) Pritchard Taylor III, MD  Compliance Officer, Attending Physician, Emergency Medicine Residency, Department of Emergency Medicine, Palmetto Health Richland, University of South Carolina School of Medicine; Medical Director, Department of Emergency Medicine, Palmetto Health Baptist

Jeter (Jay) Pritchard Taylor III, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD 

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

References

  1. Adhisivam B, Mahadevan S. Abscess of the nasal septum with staphylococcal scalded skin syndrome. Indian Pediatr. Apr 2006;43(4):372-3. [Medline].

  2. Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol. May 2002;118(5):845-50. [Medline].

  3. Hanakawa Y, Stanley JR. Mechanisms of blister formation by staphylococcal toxins. J Biochem. Dec 2004;136(6):747-50. [Medline].

  4. Ladhani S. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus. FEMS Immunol Med Microbiol. Nov 28 2003;39(2):181-9. [Medline].

  5. Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: diagnosis and management. Am J Clin Dermatol. 2003;4(3):165-75. [Medline].

  6. Rydzewska-Rosolowska A, Brzosko S, Borawski J, Mysliwiec M. Staphylococcal scalded skin syndrome in the course of lupus nephritis. Nephrology (Carlton). Jun 2008;13(3):265-6. [Medline].

  7. Murono K, Fujita K, Yoshioka H. Microbiologic characteristics of exfoliative toxin-producing Staphylococcus aureus. Pediatr Infect Dis J. May 1988;7(5):313-5. [Medline].

  8. Hayward A, Knott F, Petersen I, Livermore DM, Duckworth G, Islam A. Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England. Emerg Infect Dis. May 2008;14(5):720-6. [Medline].

  9. Decleire PY, Blondiaux G, Delaere B, Glupczynski Y. Staphyloccocal scalded skin syndrome in an adult. Acta Clin Belg. Nov-Dec 2004;59(6):365-8. [Medline].

  10. Oono T, Kanzaki H, Yoshioka T, Arata J. Staphylococcal scalded skin syndrome in an adult. Identification of exfoliative toxin A and B genes by polymerase chain reaction. Dermatology. 1997;195(3):268-70. [Medline].

  11. Shirin S, Gottlieb AB, Stahl EB. Staphylococcal scalded skin syndrome in an immunocompetent adult: possible implication of low-dosage prednisone. Cutis. Nov 1998;62(5):223-4. [Medline].

  12. Wong GW, Oppenheimer SJ, Evans RM, Leung SS, Cheng JC. Pyomyositis and staphylococcal scalded skin syndrome. Acta Paediatr. Jan 1993;82(1):113-5. [Medline].

  13. Norbury WB, Gallagher JJ, Herndon DN, Branski LK, Oehring PE, Jeschke MG. Neonate twin with staphylococcal scalded skin syndrome from a renal source. Pediatr Crit Care Med. Mar 2010;11(2):e20-3. [Medline].

  14. Kadam S, Tagare A, Deodhar J, Tawade Y, Pandit A. Staphylococcal scalded skin syndrome in a neonate. Indian J Pediatr. Oct 2009;76(10):1074. [Medline].

  15. Kapoor V, Travadi J, Braye S. Staphylococcal scalded skin syndrome in an extremely premature neonate: a case report with a brief review of literature. J Paediatr Child Health. Jun 2008;44(6):374-6. [Medline].

  16. O'Connell NH, Mannix M, Philip RK, MacDonagh-White C, Slevin B, Monahan R, et al. Infant Staphylococcal scalded skin syndrome, Ireland, 2007--preliminary outbreak report. Euro Surveill. Jun 14 2007;12(6):E070614.5. [Medline].

  17. Duijsters CE, Halbertsma FJ, Kornelisse RF, Arents NL, Andriessen P. Recurring staphylococcal scalded skin syndrome in a very low birth weight infant: a case report. J Med Case Reports. 2009;3:7313. [Medline].

  18. El Helali N, Carbonne A, Naas T, Kerneis S, Fresco O, Giovangrandi Y, et al. Nosocomial outbreak of staphylococcal scalded skin syndrome in neonates: epidemiological investigation and control. J Hosp Infect. Oct 2005;61(2):130-8. [Medline].

  19. Brewer JD, Hundley MD, Meves A, Hargreaves J, McEvoy MT, Pittelkow MR. Staphylococcal scalded skin syndrome and toxic shock syndrome after tooth extraction. J Am Acad Dermatol. Aug 2008;59(2):342-6. [Medline].

  20. Moss C, Gupta E. The Nikolsky sign in staphylococcal scalded skin syndrome. Arch Dis Child. Sep 1998;79(3):290. [Medline].

  21. Uzun S, Durdu M. The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. J Am Acad Dermatol. Mar 2006;54(3):411-5. [Medline].

  22. Acland KM, Darvay A, Griffin C, Aali SA, Russell-Jones R. Staphylococcal scalded skin syndrome in an adult associated with methicillin-resistant Staphylococcus aureus. Br J Dermatol. Mar 1999;140(3):518-20. [Medline].

  23. Ito Y, Funabashi Yoh M, Toda K, Shimazaki M, Nakamura T, Morita E. Staphylococcal scalded-skin syndrome in an adult due to methicillin-resistant Staphylococcus aureus. J Infect Chemother. Sep 2002;8(3):256-61. [Medline].

  24. Noguchi N, Nakaminami H, Nishijima S, Kurokawa I, So H, Sasatsu M. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J Clin Microbiol. Jun 2006;44(6):2119-25. [Medline].

  25. Al-Dhalimi MA. Neonatal and infantile erythroderma: a clinical and follow-up study of 42 cases. J Dermatol. May 2007;34(5):302-7. [Medline].

  26. Baartmans MG, Maas MH, Dokter J. Neonate with staphylococcal scalded skin syndrome. Arch Dis Child Fetal Neonatal Ed. Jan 2006;91(1):F25. [Medline].

  27. Chi CY, Wang SM, Lin HC, Liu CC. A clinical and microbiological comparison of Staphylococcus aureus toxic shock and scalded skin syndromes in children. Clin Infect Dis. Jan 15 2006;42(2):181-5. [Medline].

  28. Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults. A clinical review illustrated with a new case. J Am Acad Dermatol. Feb 1994;30(2 Pt 2):319-24. [Medline].

  29. El Helali N, Carbonne A, Naas T, et al. Nosocomial outbreak of staphylococcal scalded skin syndrome in neonates: epidemiological investigation and control. J Hosp Infect. Oct 2005;61(2):130-8. [Medline].

  30. Ginsburg CM. Staphylococcal toxin syndromes. Pediatr Infect Dis J. Apr 1991;10(4):319-21. [Medline].

  31. Greenwood JE, Dunn KW, Davenport PJ. Experience with severe extensive blistering skin disease in a paediatric burns unit. Burns. Feb 2000;26(1):82-7. [Medline].

  32. Hedrick J. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr Drugs. 2003;5 Suppl 1:35-46. [Medline].

  33. Hochman MA, Mayers M. Stevens-Johnson syndrome, epidermolysis bullosa, staphylococcal scalded skin syndrome, and dermatitis herpetiformis. Int Ophthalmol Clin. Spring 1997;37(2):77-92. [Medline].

  34. Johnston GA. Treatment of bullous impetigo and the staphylococcal scalded skin syndrome in infants. Expert Rev Anti Infect Ther. Jun 2004;2(3):439-46. [Medline].

  35. Ladhani S, Evans RW. Staphylococcal scalded skin syndrome. Arch Dis Child. Jan 1998;78(1):85-8. [Medline].

  36. Ladhani S, Joannou CL, Lochrie DP, Evans RW, Poston SM. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome. Clin Microbiol Rev. Apr 1999;12(2):224-42. [Medline].

  37. Lina G, Gillet Y, Vandenesch F, Jones ME, Floret D, Etienne J. Toxin involvement in staphylococcal scalded skin syndrome. Clin Infect Dis. Dec 1997;25(6):1369-73. [Medline].

  38. Payne AS, Hanakawa Y, Amagai M, Stanley JR. Desmosomes and disease: pemphigus and bullous impetigo. Curr Opin Cell Biol. Oct 2004;16(5):536-43. [Medline].

  39. Prevost G, Couppie P, Monteil H. Staphylococcal epidermolysins. Curr Opin Infect Dis. Apr 2003;16(2):71-6. [Medline].

  40. Resnick SD. Staphylococcal toxin-mediated syndromes in childhood. Semin Dermatol. Mar 1992;11(1):11-8. [Medline].

  41. Rodriguez Prieto MA, Manchado Lopez P, Ruiz Gonzalez I. Toxic epidermal necrolysis associated with scalded skin syndrome in an adult. Int J Dermatol. Nov 1997;36(11):875-6. [Medline].

  42. Shelley ED, Shelley WB, Talanin NY. Chronic staphylococcal scalded skin syndrome. Br J Dermatol. Aug 1998;139(2):319-24. [Medline].

  43. Veien NK. The clinician's choice of antibiotics in the treatment of bacterial skin infection. Br J Dermatol. Dec 1998;139 Suppl 53:30-6. [Medline].

  44. Whittock NV, Bower C. Targetting of desmoglein 1 in inherited and acquired skin diseases. Clin Exp Dermatol. Jul 2003;28(4):410-5. [Medline].

  45. Williams RE, MacKie RM. The staphylococci. Importance of their control in the management of skin disease. Dermatol Clin. Jan 1993;11(1):201-6. [Medline].

  46. Wooldridge WE. Managing skin infections in children. Postgrad Med. Mar 1991;89(4):109-12. [Medline].

  47. Yamasaki O, Yamaguchi T, Sugai M, et al. Clinical manifestations of staphylococcal scalded-skin syndrome depend on serotypes of exfoliative toxins. J Clin Microbiol. Apr 2005;43(4):1890-3. [Medline].

 
Previous
Next
 
Staphylococcal scalded skin syndrome. Photograph by David Effron, MD, FACEP.
Staphylococcal scalded skin syndrome. Photograph by David Effron, MD, FACEP.
Staphylococcal scalded skin syndrome. Photograph by David Effron, MD, FACEP.
Staphylococcal scalded skin syndrome. Photograph by David Effron, MD, FACEP.
Staphylococcal scalded skin syndrome. Photograph by David Effron, MD, FACEP.
Staphylococcal scalded skin syndrome. Photograph by David Effron, MD, FACEP.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.